Familial hemophagocytic lymphohistiocytosis 5
MONDO:0013135Any genetic hemophagocytic lymphohistiocytosis in which the cause of the disease is a mutation in the STXBP2 gene.
Also known as: FHL5, STXBP2 genetic hemophagocytic lymphohistiocytosis, familial hemophagocytic lymphohistiocytosis type 5, genetic hemophagocytic lymphohistiocytosis caused by mutation in STXBP2, hemophagocytic lymphohistiocytosis, familial, 5, with or without microvillus inclusion disease, hemophagocytic lymphohistiocytosis, familial, type 5, hemophagocytic lymphohistiocytosis, familial, 5
41 clinical trials for this condition and its sub-types, 0 tagged with Familial hemophagocytic lymphohistiocytosis 5 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New shot could help Immune-Compromised patients fight infections
Disease control OngoingThis phase 3 trial is testing a new medicine called Newnorm, a concentrated antibody solution given as a shot under the skin, in 50 people with primary immunodeficiency (a condition where the immune system doesn't work properly). The goal is to see if Newnorm can prevent serious …
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New antibody therapy aims to shield kids with rare immune disease from deadly infections
Disease control OngoingThis study tests a medicine called Kedrion IVIG 10% in 30 children with primary immunodeficiency, a condition where the immune system doesn't work properly. The treatment is made from donated antibodies and is given through a vein to help prevent serious bacterial infections. Res…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Quick-Push immune therapy studied for safety and ease
Disease control OngoingThis study looks at whether giving Cutaquig® (a medicine that helps fight infections) by a faster manual push method is safe and easy for adults with primary or secondary immunodeficiency. About 36 participants will use the rapid push method at home. The goal is to see if this ap…
Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New antibody therapy tested for long-term safety in immune-deficient patients
Disease control OngoingThis study tests the long-term safety of TAK-881, a subcutaneous immunoglobulin treatment, in 53 adults and children with primary immunodeficiency diseases (PIDD) who completed a prior study. Participants receive regular infusions every 2-4 weeks and are monitored for side effect…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Scientists collect skin cells to pave way for future immune disease cures
Knowledge-focused By invitation onlyThis study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC